The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of metformin on prostate cancer (PC) outcomes in the E3805 CHAARTED trial.
 
David Frazier Jarrard
No Relationships to Disclose
 
Yu-Hui Chen
No Relationships to Disclose
 
Glenn Liu
No Relationships to Disclose
 
Michael Anthony Carducci
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Clovis Oncology; Medivation; Merck
 
Mario A. Eisenberger
Honoraria - Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ipsen; Sanofi
Research Funding - Genentech; Sanofi; Tokai Pharmaceuticals
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Sanofi
 
Yu-Ning Wong
Research Funding - Pfizer (Inst); PhRMA Foundation; Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Tokai Pharmaceuticals
 
Noah M. Hahn
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Inovio Pharmaceuticals; Oncogenex; Pieris Pharmaceuticals
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Heat Biologics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Principa Biopharma (Inst)
 
Manish Kohli
No Relationships to Disclose
 
Matthew M. Cooney
Consulting or Advisory Role - Bayer
 
Robert Dreicer
Honoraria - Astellas Pharma
Consulting or Advisory Role - Asana Biosciences; Astellas Pharma; Exelixis; Ferring; Janssen Oncology; Medivation; Roche
Research Funding - Asana Biosciences (Inst); Genentech (Inst)
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Dendreon; Endocyte; Janssen Oncology; Mannkind; Pfizer; UpToDate
Consulting or Advisory Role - Amgen; AVEO; Bayer; BIND Biosciences; Cerulean Pharma; Churchill Pharmaceuticals; Genentech/Roche; HERON; Janssen Biotech; Labceutics; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Caris MPI; Dendreon; Genentech/Roche; GlaxoSmithKline; Medivation; Millennium; Pfizer; Sanofi
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology
 
Joel Picus
Consulting or Advisory Role - Novo Nordisk
Research Funding - Agensys; Altor BioScience; Astex Pharmaceuticals; BioClin Therapeutics; Mirati Therapeutics; Novartis; Oncogenex
 
Daniel H. Shevrin
No Relationships to Disclose
 
Maha Hussain
Consulting or Advisory Role - AstraZeneca; Essa; Johnson & Johnson; Synthon
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech (Inst); Medivation (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
 
Jorge A. Garcia
Consulting or Advisory Role - Bayer; Eisai; Exelixis; Genentech/Roche; Medivation; Pfizer; Sanofi
Speakers' Bureau - Bayer; Genentech/Roche; Medivation/Astellas; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Lilly (Inst); Orion (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Exelixis; Genentech/Roche; Medivation/Astellas; Pfizer; Sanofi
 
Robert S. DiPaola
Research Funding - Abbvie (Inst)
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen Biotech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination